Victory Capital Management Inc. Grows Position in Sarepta Therapeutics, Inc. (NASDAQ:SRPT)

Victory Capital Management Inc. increased its position in shares of Sarepta Therapeutics, Inc. (NASDAQ:SRPTGet Rating) by 449.6% in the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 196,454 shares of the biotechnology company’s stock after purchasing an additional 160,708 shares during the period. Victory Capital Management Inc. owned approximately 0.22% of Sarepta Therapeutics worth $21,716,000 at the end of the most recent quarter.

A number of other large investors have also recently made changes to their positions in SRPT. Assenagon Asset Management S.A. boosted its stake in shares of Sarepta Therapeutics by 154.8% during the 3rd quarter. Assenagon Asset Management S.A. now owns 1,129,016 shares of the biotechnology company’s stock worth $124,801,000 after purchasing an additional 685,845 shares during the period. Wellington Management Group LLP lifted its holdings in Sarepta Therapeutics by 33.6% during the 1st quarter. Wellington Management Group LLP now owns 2,680,478 shares of the biotechnology company’s stock valued at $209,399,000 after buying an additional 673,725 shares in the last quarter. Prudential Financial Inc. lifted its holdings in Sarepta Therapeutics by 1,473.5% during the 1st quarter. Prudential Financial Inc. now owns 396,074 shares of the biotechnology company’s stock valued at $30,942,000 after buying an additional 370,902 shares in the last quarter. Bellevue Group AG lifted its holdings in Sarepta Therapeutics by 39.2% during the 1st quarter. Bellevue Group AG now owns 1,151,159 shares of the biotechnology company’s stock valued at $89,929,000 after buying an additional 324,418 shares in the last quarter. Finally, Renaissance Technologies LLC lifted its holdings in Sarepta Therapeutics by 164.3% during the 2nd quarter. Renaissance Technologies LLC now owns 393,278 shares of the biotechnology company’s stock valued at $29,480,000 after buying an additional 244,478 shares in the last quarter. 87.31% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

SRPT has been the subject of a number of research analyst reports. Cowen lifted their price objective on shares of Sarepta Therapeutics from $114.00 to $125.00 in a report on Wednesday, January 11th. Needham & Company LLC lifted their price objective on shares of Sarepta Therapeutics from $158.00 to $160.00 and gave the company a “buy” rating in a report on Tuesday, January 10th. Morgan Stanley lifted their price objective on shares of Sarepta Therapeutics from $135.00 to $141.00 and gave the company an “equal weight” rating in a report on Thursday, October 13th. StockNews.com assumed coverage on shares of Sarepta Therapeutics in a report on Wednesday, October 12th. They issued a “hold” rating for the company. Finally, The Goldman Sachs Group boosted their price target on shares of Sarepta Therapeutics from $152.00 to $171.00 and gave the company a “buy” rating in a report on Thursday, November 3rd. Three investment analysts have rated the stock with a hold rating and seven have issued a buy rating to the company. According to data from MarketBeat, Sarepta Therapeutics currently has a consensus rating of “Moderate Buy” and a consensus target price of $150.14.

Insider Buying and Selling

In related news, Director Stephen Mayo sold 858 shares of the business’s stock in a transaction that occurred on Thursday, November 17th. The shares were sold at an average price of $109.92, for a total transaction of $94,311.36. Following the completion of the transaction, the director now owns 6,387 shares in the company, valued at approximately $702,059.04. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. 6.40% of the stock is currently owned by company insiders.

Sarepta Therapeutics Trading Up 0.0 %

NASDAQ SRPT opened at $128.37 on Wednesday. The company has a quick ratio of 3.99, a current ratio of 4.36 and a debt-to-equity ratio of 3.58. The firm has a market cap of $11.27 billion, a PE ratio of -15.64 and a beta of 1.04. The company has a 50 day moving average price of $122.74 and a 200 day moving average price of $111.59. Sarepta Therapeutics, Inc. has a 52 week low of $61.28 and a 52 week high of $134.08.

Sarepta Therapeutics (NASDAQ:SRPTGet Rating) last posted its quarterly earnings data on Wednesday, November 2nd. The biotechnology company reported ($2.94) EPS for the quarter, missing the consensus estimate of ($1.21) by ($1.73). The firm had revenue of $230.30 million for the quarter, compared to the consensus estimate of $234.55 million. Sarepta Therapeutics had a negative return on equity of 97.37% and a negative net margin of 81.76%. The company’s revenue was up 21.6% compared to the same quarter last year. During the same quarter last year, the firm earned ($0.60) EPS. As a group, sell-side analysts forecast that Sarepta Therapeutics, Inc. will post -8.09 EPS for the current fiscal year.

About Sarepta Therapeutics

(Get Rating)

Sarepta Therapeutics, Inc is a commercial-stage biopharmaceutical company, which is engaged in the discovery and development of therapeutics for the treatment of rare diseases. The company was founded on July 22, 1980, and is headquartered in Cambridge, MA.

See Also

Institutional Ownership by Quarter for Sarepta Therapeutics (NASDAQ:SRPT)

Receive News & Ratings for Sarepta Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sarepta Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.